Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394397 | 0.84 | KDM4E (0.36) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL676126 | 0.76 | KIF11 (0.51) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL21645575 | 0.70 | CYP1A2 (0.49) | KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL675470 | 0.70 | KDM4E (0.55) | KDM4EKMT2AADORA1ADORA2AALDH1A1 | |
| SCHEMBL675071 | 0.70 | KIF11 (0.58) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL679355 | 0.69 | ADORA2A (0.57) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL674852 | 0.68 | KDM4E (0.43) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL676055 | 0.67 | CA5A (0.62) | KDM4EKMT2AADORA1ADORA2AMEN1 | |
| SCHEMBL675713 | 0.67 | TLR8 (0.46) | KDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL34463365 | 0.66 | ALDH1A1 (0.44) | KDM4EKMT2AADORA1ADORA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010025872-A2 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2010-03-11 | — | — | WO | disclosed |